COMPANY PROFILE

Windward Bio

Biopharmaceutical company advancing treatments for oncology, immunology, and rare diseases with a focus on commercialization

Basel, SwitzerlandFounded 2024Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Windward Bio

Windward Bio operates in the biopharmaceutical sector, focusing on the development and commercialization of treatments for oncology, immunology, and rare diseases. The company leverages the extensive experience of its leadership team, which includes professionals with backgrounds in corporate finance, capital markets, and global product strategy. Windward Bio's business model centers around advancing drug programs from discovery research through to commercialization, targeting unmet medical needs in various therapeutic areas. The company serves a diverse client base, including healthcare providers and patients, by offering innovative solutions that address complex medical conditions. Revenue generation is primarily driven by the successful launch and commercialization of its drug products. The market in which Windward Bio operates is highly competitive, with a strong emphasis on scientific research and clinical development. The company's strategic approach involves collaboration with industry partners and advisory boards to enhance its product offerings and expand its market reach.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2024
Headquarters: Basel, Switzerland
Employees: 11
Open positions: 1
Dealroom signal: 95.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Immune System, Rumoured $1B, Biotech and Pharma, Rare Diseases, DT and LS, science-based, Swiss DT Biotech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	May 2026	$165M	$660M	Sanofi · SR One · RTW Investments · RA Capital Management	↗
SERIES AOther financing	Jan 2025	$200M	$800M	Omega Funds · RTW Investments · Quan Capital · Pivotal BioVenture Partners	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Windward Bio website traffic

Latest recorded traffic for Windward Bio is 2.5K monthly website visits, up 25% over the last three months. Windward Bio's team grew 0% over the past year.

Latest monthly visits2.5K 3-month web change+25% 1-year team growth0%

Monthly website visitsMar 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Regulatory Affairs ManagerBasel, Switzerland · Legal · Jun 11, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BTBright Peak TherapeuticsDeveloping next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases	Basel, Switzerland	Operational	36	$232M	$535M
IOiOncturaOncology therapies countering immunosuppression in tumors	Geneva, Switzerland	Operational
ITImmunos TherapeuticsDeveloping the next generation of novel immunotherapies that will improve the lives of patients with serious diseases	Zurich, Switzerland	Operational
ELEltheraBringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs	Schlieren, Switzerland	Operational
ATAmal TherapeuticsDeveloping and progressing therapeutic cancer vaccines	Geneva, Switzerland	Acquired
LBLight Chain BioscienceFormerly Novimmune. Develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders	Geneva, Switzerland	Operational
INInvectysDeveloping innovative approaches to immunotherapy to treat cancer	Paris, France	Operational
CTCytospire TherapeuticsHarnessing the immune system to create next-generation cancer treatments	London, United Kingdom	Operational